Regeneron Pharmaceuticals, Inc. Class Action Reminder from The Gross Law Firm
The Gross Law Firm is currently reminding investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) about an ongoing class action lawsuit. The deadline for potential lead plaintiffs to file a motion is March 10, 2025.
Regeneron is a biotechnology company known for developing and producing medications to treat various diseases. The class action lawsuit focuses on allegations that Regeneron and its executives made materially false and misleading statements regarding the Company’s business practices. It is claimed that these statements led to inflated stock prices, ultimately misleading investors.
The lawsuit alleges that Regeneron failed to disclose the full extent of a U.S. Food and Drug Administration (FDA) investigation into the Company’s business practices. This investigation apparently stemmed from allegations of improper relationships between Regeneron employees and healthcare providers, potentially violating FDA regulations.
Following the revelation of the FDA investigation, Regeneron’s stock price dropped significantly, causing financial losses for investors who had relied on the Company’s earlier statements. The class action lawsuit seeks to hold Regeneron accountable for these alleged violations of securities laws and to recover damages on behalf of affected investors.
Investors who purchased Regeneron stock between a certain period and suffered financial losses as a result may be eligible to participate in the class action lawsuit. The deadline for lead plaintiffs to file a motion is March 10, 2025. It is important for eligible investors to take action promptly to ensure their rights are protected and to potentially recover damages incurred as a result of the alleged misconduct.
Those considering participation in the class action lawsuit should seek legal advice to understand their rights and options. By joining the lawsuit, eligible investors may have the opportunity to recover financial losses and hold Regeneron accountable for any alleged securities law violations.
In conclusion, investors of Regeneron Pharmaceuticals, Inc. should be aware of the pending class action lawsuit and the upcoming deadline for lead plaintiffs to file a motion. Seeking legal counsel and taking appropriate action can help potentially recover losses incurred due to alleged securities law violations by the Company and its executives.
